Choong Ang Vaccine Laboratory Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 28, 2022 at 01:21 am
Share
Choong Ang Vaccine Laboratory Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported negative sales was KRW 0.00036 million compared to KRW 0.00015 million a year ago. Net income was KRW 1,974.33 million compared to KRW 1,485.33 million a year ago. Basic earnings per share from continuing operations was KRW 202 compared to KRW 151 a year ago. Diluted earnings per share from continuing operations was KRW 202 compared to KRW 151 a year ago. Basic earnings per share was KRW 202 compared to KRW 151 a year ago.
For the nine months, negative sales was KRW 0.00002 million compared to KRW 0.00041 million a year ago. Net income was KRW 5,731.68 million compared to KRW 5,257.92 million a year ago. Basic earnings per share from continuing operations was KRW 587 compared to KRW 533 a year ago. Diluted earnings per share from continuing operations was KRW 587 compared to KRW 533 a year ago. Basic earnings per share was KRW 587 compared to KRW 533 a year ago.
Choong Ang Vaccine Laboratory Co., Ltd. is a Korea-based company mainly engaged in the manufacturing and marketing of veterinary vaccines. The Company provides veterinary vaccines for fowl, dogs, pigs, cattle, rabbits, cats, fishes and others under the brand name SuiShot, PoulShot, Canishot, BoviShot, FeliShot, RabbiShot and AquaShot. The Company also provides diagnosis services, and distributes other veterinary drugs, such as antibiotics, anthelmintics, disinfectants and feed additives. The Company distributes its products within domestic market and to overseas markets.
CHOONG ANG VACCINE LABORATORY CO., LTD. 
